Virtu Financial LLC Makes New $240,000 Investment in Novavax, Inc. (NASDAQ:NVAX)

Virtu Financial LLC acquired a new stake in shares of Novavax, Inc. (NASDAQ:NVAX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,830 shares of the biopharmaceutical company’s stock, valued at approximately $240,000.

Other institutional investors have also modified their holdings of the company. Spire Wealth Management purchased a new stake in Novavax during the 4th quarter valued at $29,000. KBC Group NV raised its stake in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 3,917 shares during the period. TigerOak Management L.L.C. bought a new stake in shares of Novavax in the 4th quarter worth about $86,000. AlphaQuest LLC boosted its stake in shares of Novavax by 290.1% during the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 7,940 shares during the period. Finally, Xponance Inc. bought a new position in Novavax during the 4th quarter valued at about $95,000. 53.04% of the stock is owned by institutional investors.

Novavax Stock Down 3.6 %

NVAX opened at $7.00 on Friday. The stock’s fifty day moving average is $8.13 and its two-hundred day moving average is $9.37. The company has a market capitalization of $1.13 billion, a P/E ratio of -3.10, a PEG ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 52 week low of $3.81 and a 52 week high of $23.86.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same quarter in the prior year, the business posted ($1.44) EPS. Equities analysts anticipate that Novavax, Inc. will post -1.46 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on NVAX. BTIG Research began coverage on Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 target price for the company. TD Cowen upgraded Novavax to a “hold” rating in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 target price on shares of Novavax in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $18.00.

Insider Activity

In related news, Director James F. Young sold 5,400 shares of Novavax stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now directly owns 51,760 shares of the company’s stock, valued at $414,080. This trade represents a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.00% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.